I’ve heard various definitions of what a “response” is however two seem the most common. One is a 30% reduction in tumor size or count. The other is basically the same except the reduction is 50%.
But yeah, then there is “clinical benefit” which includes any effect (like mixed, slower progression and stable disease) and that is easily seen in the overall survival numbers.
And this combo is most impressive in that regard, so much so they’ve not gotten to the “average” survival yet (which I believe is 50% survival) as the curves have a pronounced “tail” (it flattens out with time).
Good stuff.
Jeff